Yeji

$MGTX

MeiraGTx Holdings plc

Runway:cash-flow +
NasdaqMarket cap: —CIK 0001735438

Upcoming catalysts

0 surfaced

No catalysts surfaced for MGTX yet.

Drug pipeline

Ocular assessments
Achromatopsia
AAV OPTIRPE65
Leber Congenital Amaurosis (LCA)
AAV2hAQP1
Squamous Cell Head and Neck Cancer
AAV-GAD Low Dose
Parkinson's Disease
Prior exposure to AAV-CNGA3 or AAV-CNGB3
Achromatopsia
AAV RPE65
Leber Congenital Amaurosis
adeno-associated virus vector AAV- CNGA3
Achromatopsia
AAV2hAQP1: 1 x 10^11 vg/gland (single gland)
Radiation-Induced Parotid Gland Hypofunction
AAV - CNGB3
Achromatopsia
AAV-GAD
Parkinson's Disease
AAV5-RPGR
X-Linked Retinitis Pigmentosa
AAV2-hAQP1 Concentration 1
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
AAV2-hAQP1
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT06544798AAV2-hAQP1Phase 2Enrolling By Invitation2032-02-01
NCT05894343AAV-GADPhase 2Active Not Recruiting2029-10-01
NCT05060341——Active Not Recruiting2027-03-01
NCT05926765AAV2-hAQP1 Concentration 1Phase 2Recruiting2026-12-01
NCT02446249AAV2hAQP1Phase 1Active Not Recruiting2026-07-01
NCT05603312AAV-GAD Low DosePhase 2Completed2024-09-06
NCT03349242——Completed2024-04-19
NCT03278873Prior exposure to AAV-CNGA3 or AAV-CNGB3—Terminated2024-04-04
NCT02714816——Completed2023-07-22
NCT02946879AAV OPTIRPE65—Completed2023-07-01
NCT04124185Ocular assessments—Completed2023-05-18
NCT04043104AAV2hAQP1: 1 x 10^11 vg/gland (single gland)Phase 1Completed2023-03-28
NCT03252847AAV5-RPGRPhase 2Completed2021-11-18
NCT03758404adeno-associated virus vector AAV- CNGA3Phase 2Completed2021-06-10
NCT03001310AAV - CNGB3Phase 2Completed2019-10-25
NCT02781480AAV RPE65Phase 2Completed2018-12-01